Certain NSCLC Subgroups May Not Benefit From Immunotherapy Certain NSCLC Subgroups May Not Benefit From Immunotherapy

A comprehensive study exploring NSCLC subgroup responses to immunotherapy may help determine which patients are less likely to benefit from these agents.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news